Stay updated on Tazemetostat + Pembrolizumab in Urothelial Carcinoma Clinical Trial

Sign up to get notified when there's something new on the Tazemetostat + Pembrolizumab in Urothelial Carcinoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Tazemetostat + Pembrolizumab in Urothelial Carcinoma Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    Change Detected
    Summary
    The value on the webpage has changed from '08 University of Kansas Health System Centers 07 08' to '16 University Health Center 15 (Estimated) 16'. This change likely reflects an update or modification related to medical and healthcare-related services provided by the University of Kansas Health System.
    Difference
    0.4%
    Check dated 2024-05-17T02:24:46.000Z thumbnail image
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    9 days ago
    Change Detected
    Summary
    The value (Estimated) has recently changed to . This change likely indicates an update or revision in the estimated completion date for a medical study related to testing the addition of Tazemetostat to the immunotherapy drug Pembrolizumab in treating patients with urothelial carcinoma.
    Difference
    0.0%
    Check dated 2024-05-10T08:14:14.000Z thumbnail image
  7. Check
    10 days ago
    Change Detected
    Summary
    The value 01 04 30 01 has recently changed to 08 05 07 (Estimated) 08. This change likely represents an update in the study details or progress of the clinical trial related to testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab in Advanced Urothelial Carcinoma.
    Difference
    0.2%
    Check dated 2024-05-09T01:49:45.000Z thumbnail image
  8. Check
    16 days ago
    Change Detected
    Summary
    The value (Estimated) on the webpage has recently changed to . This change likely indicates an update or revision in the estimated completion date for a medical and healthcare-related study on the addition of Tazemetostat to Pembrolizumab in treating advanced Urothelial Carcinoma.
    Difference
    0.0%
    Check dated 2024-05-03T06:57:25.000Z thumbnail image
  9. Check
    17 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 03 21 03 20 03 21 to 05 01 04 30 (Estimated) 05 01. This change likely represents an update in the estimated primary completion date of the medical study related to testing the addition of Tazemetostat to Pembrolizumab in treating patients with urothelial carcinoma.
    Difference
    0.3%
    Check dated 2024-05-02T03:16:10.000Z thumbnail image
  10. Check
    18 days ago
    Change Detected
    Difference
    0.5%
    Check dated 2024-04-30T22:14:30.000Z thumbnail image

Stay in the know with updates to Tazemetostat + Pembrolizumab in Urothelial Carcinoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Tazemetostat + Pembrolizumab in Urothelial Carcinoma Clinical Trial page.